According to the World Health Organization (WHO), chronic obstructive pulmonary disease (COPD) is the third leading cause of ...

Those battling severe asthma, upper respiratory tract diseases, Chronic Obstructive Pulmonary Disease (COPD), Asbestosis and ...

“The brain is the gatekeeper of longevity,” said Wyss-Coray. “If you’ve got an old brain, you have an increased likelihood of ...

This acquisition of Verona Pharma reflects the commitment we have to delivering innovative treatments to patients and our ...

After the Veterans Health Administration tweaked its formulary on an asthma and chronic obstructive pulmonary disease therapy, hospitalizations and emergency department visits increased, according to ...

Poultry consumption, vigorous exercise, and oily fish consumption were among the factors correlated with biologically ...

Former Chicago alderman Carrie Austin, indicted in 2021 for allegedly receiving home improvements from contractors seeking ...

Verona Pharma plc (NASDAQ:VRNA) is one of the 11 Best Mid-cap Healthcare Stocks to Buy According to Hedge Funds.

The deal gives Merck access to Verona Pharma’s new chronic obstructive pulmonary disease medication Ohtuvayre.

The move bolsters Merck's lineup as it braces for the 2028 loss of patent exclusivity for blockbuster cancer drug Keytruda.

In the second largest M&A deal of the year, Merck & Co. Inc. has strengthened its cardiopulmonary portfolio with the $10 ...

Substantial challenges characterise the management of chronic obstructive pulmonary disease (COPD), including a progressively ...